WO2021109791A1 - 一种以ba为原料合成熊去氧胆酸的方法 - Google Patents
一种以ba为原料合成熊去氧胆酸的方法 Download PDFInfo
- Publication number
- WO2021109791A1 WO2021109791A1 PCT/CN2020/126922 CN2020126922W WO2021109791A1 WO 2021109791 A1 WO2021109791 A1 WO 2021109791A1 CN 2020126922 W CN2020126922 W CN 2020126922W WO 2021109791 A1 WO2021109791 A1 WO 2021109791A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- reaction
- solvent
- ethylene glycol
- Prior art date
Links
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 title claims abstract description 45
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 title claims abstract description 42
- 229960001661 ursodiol Drugs 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 32
- 239000002994 raw material Substances 0.000 title claims abstract description 30
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 270
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 234
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 43
- 238000007239 Wittig reaction Methods 0.000 claims abstract description 40
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 claims abstract description 40
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 22
- 238000006722 reduction reaction Methods 0.000 claims abstract description 18
- 230000007062 hydrolysis Effects 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims description 128
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 99
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 98
- 239000002904 solvent Substances 0.000 claims description 92
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 78
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 72
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 39
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 37
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 35
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical group ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims description 32
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 25
- 239000007800 oxidant agent Substances 0.000 claims description 24
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 18
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 230000001590 oxidative effect Effects 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 14
- 239000012312 sodium hydride Substances 0.000 claims description 14
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 claims description 12
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 12
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims description 12
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 11
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 10
- 230000009471 action Effects 0.000 claims description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- -1 methoxyformylmethylene Chemical group 0.000 claims description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 8
- 230000035484 reaction time Effects 0.000 claims description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- IFMZTQNYAXMLFK-UHFFFAOYSA-N propyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCCC)C1=CC=CC=C1 IFMZTQNYAXMLFK-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000007868 Raney catalyst Substances 0.000 claims description 5
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 5
- NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 claims description 5
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 4
- DVQMPWOLBFKUMM-UHFFFAOYSA-M 2-diethoxyphosphorylacetate Chemical compound CCOP(=O)(CC([O-])=O)OCC DVQMPWOLBFKUMM-UHFFFAOYSA-M 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- JQHSPYGRKOQBSU-UHFFFAOYSA-N propyl 2-diethoxyphosphorylacetate Chemical compound CCCOC(=O)CP(=O)(OCC)OCC JQHSPYGRKOQBSU-UHFFFAOYSA-N 0.000 claims description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 2
- UYVVLXVBEQAATF-UHFFFAOYSA-N 4-(1,3,7,12-tetrahydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid Chemical compound OC1CC2CC(O)CC(O)C2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 UYVVLXVBEQAATF-UHFFFAOYSA-N 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- OSNIIMCBVLBNGS-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one Chemical compound CN(C)C(C)C(=O)C1=CC=C2OCOC2=C1 OSNIIMCBVLBNGS-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- RLAHWVDQYNDAGG-UHFFFAOYSA-N Methanetriol Chemical compound OC(O)O RLAHWVDQYNDAGG-UHFFFAOYSA-N 0.000 claims 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 19
- 230000015572 biosynthetic process Effects 0.000 abstract description 18
- 230000009467 reduction Effects 0.000 abstract description 10
- 238000009776 industrial production Methods 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000010511 deprotection reaction Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 40
- 239000000243 solution Substances 0.000 description 25
- 238000010898 silica gel chromatography Methods 0.000 description 22
- 238000001514 detection method Methods 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 14
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 239000005909 Kieselgur Substances 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- ZNWOYQVXPIEQRC-ZRFCQXGJSA-N (8s,9s,10r,13s,14s,17r)-17-(1-hydroxypropan-2-yl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(CO)C)[C@@]1(C)CC2 ZNWOYQVXPIEQRC-ZRFCQXGJSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000010992 reflux Methods 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 0 C[C@@](C(CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CCC2(C3)OCCO2)C3=CC1)C=CC(O*)=O Chemical compound C[C@@](C(CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CCC2(C3)OCCO2)C3=CC1)C=CC(O*)=O 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 4
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CBOPJBXPWAGGGD-VCGIBUFOSA-N C[C@@H](C(CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CCC2(C3)OCCO2)C3=CC1)C=O Chemical compound C[C@@H](C(CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CCC2(C3)OCCO2)C3=CC1)C=O CBOPJBXPWAGGGD-VCGIBUFOSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OPGYCKDTPNLLCZ-CHNGHHIASA-N OC[C@H]([C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=O)C.OCC([C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=O)C Chemical compound OC[C@H]([C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=O)C.OCC([C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=O)C OPGYCKDTPNLLCZ-CHNGHHIASA-N 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LLJFNWVJKMVHIL-UHFFFAOYSA-N (2-methoxy-2-oxoethyl)phosphonic acid Chemical compound COC(=O)CP(O)(O)=O LLJFNWVJKMVHIL-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- DKPMWHFRUGMUKF-UHFFFAOYSA-N (3alpha,5alpha,6alpha,7alpha)-3,6,7-Trihydroxycholan-24-oic acid Natural products OC1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DKPMWHFRUGMUKF-UHFFFAOYSA-N 0.000 description 1
- JOYGXTIHTHBSOA-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-thiophen-2-ylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C=CC1=CC=CS1 JOYGXTIHTHBSOA-UHFFFAOYSA-N 0.000 description 1
- GSVQWRYRPRJOIM-UHFFFAOYSA-N 2-methylpropan-2-ol;sodium Chemical compound [Na].CC(C)(C)O GSVQWRYRPRJOIM-UHFFFAOYSA-N 0.000 description 1
- 208000007407 African swine fever Diseases 0.000 description 1
- CYOUPOQSMBYKHM-IYIQQQMMSA-N CCCOC(/C=C/[C@@H](C)C(CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CCC2(C3)OCCO2)C3=CC1)=O Chemical compound CCCOC(/C=C/[C@@H](C)C(CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CCC2(C3)OCCO2)C3=CC1)=O CYOUPOQSMBYKHM-IYIQQQMMSA-N 0.000 description 1
- CVVDPXRWVSDTQF-CJCYJBQESA-N CCOC(/C=C/[C@@H](C)C(CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CCC2(C3)OCCO2)C3=CC1)=O Chemical compound CCOC(/C=C/[C@@H](C)C(CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CCC2(C3)OCCO2)C3=CC1)=O CVVDPXRWVSDTQF-CJCYJBQESA-N 0.000 description 1
- GWGOLSGGNUWHBC-AJKWDUOOSA-N C[C@@H](C(CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CCC2(C3)OCCO2)C3=CC1)/C=C/C(O)=O Chemical compound C[C@@H](C(CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CCC2(C3)OCCO2)C3=CC1)/C=C/C(O)=O GWGOLSGGNUWHBC-AJKWDUOOSA-N 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 235000021190 leftovers Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Definitions
- the present invention belongs to the technical field of organic chemistry synthesis/drug synthesis, and relates to a method for synthesizing ursodeoxycholic acid, in particular to a 21-hydroxy-20-methylpregna-4-en-3-one (BA) A method for synthesizing ursodeoxycholic acid as a raw material.
- BA 21-hydroxy-20-methylpregna-4-en-3-one
- Ursodeoxycholic acid (Ursodeoxycholic acid, UDCA) (as shown in formula 1), chemical name 3 ⁇ , 7 ⁇ -dihydroxy-5 ⁇ -cholan-24-acid (3 ⁇ , 7 ⁇ -dihydroxy-5 ⁇ -cholan-24-oicacid ), CAS No. 128-13-2, molecular formula C 24 H 40 O 4 , molecular weight 392.56, white powder, odorless, bitter taste, melting point 203-204°C.
- Ursodeoxycholic acid is the main component of the precious Chinese medicine bear bile. It is the first-line treatment drug for primary biliary cirrhosis (PBC) approved by the US FDA. It can also effectively treat gallstone diseases and chronic liver diseases in clinical practice. , Has broad market prospects.
- PBC primary biliary cirrhosis
- the synthesis report of ursodeoxycholic acid mainly includes the following methods. (1) Using hyodeoxycholic acid as a raw material, 7-step reaction, ursodeoxycholic acid was synthesized with a total yield of 15% (as shown in Scheme 1, Journal) of the Chemical Society Perkin Transactions, 1990, 1:1-3.). The raw materials used in this route are cheap and easy to obtain, but the steps are cumbersome and the yield is low. At the same time, the last step of the reaction uses lithium-liquid ammonia reduction, which is more dangerous.
- ursodeoxycholic acid was synthesized with a total yield of 38% (as shown in Scheme 4, WO2014020024 A1).
- the raw materials used in this route are cheap and easily available, and the yield is acceptable, but the route is too long.
- ursodeoxycholic acid was synthesized with a total yield of 53% after 4 steps of reaction (as shown in Scheme 5, CN105503987 A). This route is short and the yield is acceptable, but the selectivity is poor during hydrogen reduction.
- ursodeoxycholic acid was synthesized with a total yield of 64% through a 2-step reaction (as shown in Scheme 6, Bioorganic&Medicinal Chemistry, 2016, 24: 3986-3993.). This route is short and the yield is relatively high, but the raw material chenodeoxycholic acid is more expensive.
- the synthetic routes of ursodeoxycholic acid that have been reported so far not only have problems such as too complicated steps, low yield, large pollution, and expensive raw materials, but also the existing synthetic routes of ursodeoxycholic acid reported above all use animal bile acids ( Bovine, sheep cholic acid, chenodeoxycholic acid, urscholic acid, hyocholic acid, hyodeoxycholic acid) are the starting materials, but due to the emergence of diseases such as avian influenza, mad cow disease, swine streptococcus and African swine fever, People have doubts about the safety of animal-derived raw materials. Therefore, the development of an efficient method for the synthesis of ursodeoxycholic acid based on plant-derived raw materials is of great significance and industrial value.
- the present invention overcomes the defects of the prior art, and uses 21-hydroxy-20-methylpregn-4-en-3-one ((20S)-21-hydroxy-20-methylpregn-4-en-3-one) Also known as BA (bisnoralcohol) as a raw material (which is obtained by biological fermentation of phytosterols) through ethylene glycol or neopentyl glycol protection, oxidation, Wittig reaction, deprotection, reduction, hydrolysis and other steps to synthesize the ursodeoxy bile acid.
- BA bisnoralcohol
- the efficient and simple method for chemically synthesizing ursodeoxycholic acid provided by the invention has the advantages of cheap and easy-to-obtain raw materials, mild reaction conditions, simple post-treatment, environmental friendliness, low cost, high yield, and convenient industrial production.
- the raw material 21-hydroxy-20-methylpregn-4-en-3-one ((20S)-21-hydroxy-20-methylpregn-4-en-3-one) used in the present invention is also called BA ( Bisnoralcohol) is derived from the fermentation of phytosterols, leftovers from the oil and fat process. It is a green raw material of plant origin. The current annual output is 1,000 tons and the price is low. It can avoid the infection of pathogenic bacteria and viruses in the prior art. ; The synthetic route of the present invention, its synthetic steps are easy to operate, high yield, environmentally friendly, and convenient for industrial production.
- the 21-hydroxy-20-methylpregna-4-en-3-one (BA) as the raw material includes, but is not limited to, obtained by biological fermentation of plant sterols, or obtained by chemical synthesis.
- the method for synthesizing ursodeoxycholic acid from 21-hydroxy-20-methylpregna-4-en-3-one (BA) raw material includes the following steps:
- the method for synthesizing ursodeoxycholic acid from 21-hydroxy-20-methylpregna-4-en-3-one (BA) as a raw material provided by the present invention further includes the following steps:
- R is an alkyl group; preferably a C1-C20 alkyl group; more preferably, a C1, C2 alkyl group.
- the ethylene glycol protection reaction means that BA, ethylene glycol, and p-toluenesulfonic acid represented by formula (1) are dissolved in the first solvent, and the ethylene glycol protection reaction occurs to obtain the formula ( 2) Compound; or, BA, ethylene glycol, p-toluenesulfonic acid, and triethyl orthoformate represented by formula (1) are dissolved in the first solvent, and the ethylene glycol protection reaction occurs to obtain the compound of formula (2);
- BA, ethylene glycol, and p-toluenesulfonic acid represented by formula (1) are dissolved in the first solvent, and the ethylene glycol protection reaction occurs to obtain the compound of formula (2).
- the first solvent is selected from one or more of benzene, toluene, ethyl acetate, tetrahydrofuran, hexane, etc.; preferably, it is benzene.
- the ethylene glycol protection reaction in step (a) is: BA, ethylene glycol, and p-toluenesulfonic acid represented by formula (1) are dissolved in the first solvent, the ethylene glycol protection reaction occurs, and the formula (2) )
- the temperature of the ethylene glycol protection reaction is 80 to 130°C, preferably 90°C; the time of the ethylene glycol protection reaction is 2 to 36 hours, preferably 24 hours.
- ethylene glycol protection reaction in step (a) is: BA, ethylene glycol, p-toluenesulfonic acid, and triethyl orthoformate represented by formula (1) are dissolved in the first solvent, ethylene glycol protection occurs
- the reaction yields a compound of formula (2); wherein the molar ratio of BA, ethylene glycol, p-toluenesulfonic acid, and triethyl orthoformate represented by formula (1) is 1: (1-50): (0.01-1) ): (1-20); preferably, 1:10:0.1:3; the temperature of the ethylene glycol protection reaction is 0-50°C, preferably room temperature 25°C; the time of the ethylene glycol protection reaction It is 2 to 36 hours, preferably 8 hours.
- the synthesis step of the compound of formula (2) includes: the BA represented by formula (1) is dissolved in a first solvent, and reacted with ethylene glycol and p-toluenesulfonic acid to protect the compound represented by formula (1)
- the 3-position carbonyl group of BA gives the compound of formula (2).
- step (b) the oxidation reaction means: the compound of formula (2), TEMPO, sodium bicarbonate, tetrabutylammonium bromide, and an oxidizing agent are dissolved in the second solvent to undergo oxidation reaction to obtain the compound of formula (3) .
- the oxidant is selected from one of N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), 2-iodoyl benzoic acid (IBX), etc. or Multiple; preferably, N-chlorosuccinimide (NCS).
- step (b) the molar ratio of the compound of formula (2), TEMPO, sodium bicarbonate, tetrabutylammonium bromide, and oxidant is 1: (0-1): (0-20): (0-1): (1-5); Preferably, it is 1:0.01:1.35:0.1:1.15.
- the second solvent is selected from one or more of dichloromethane, tetrahydrofuran, toluene, dimethyl sulfoxide, water, etc.; preferably, it is a mixed solvent of dichloromethane and water.
- step (b) the temperature of the oxidation reaction is 0-30°C; preferably, it is 0°C.
- step (b) the oxidation reaction time is 2-8h; preferably, it is 5h.
- the synthesis step of the compound of formula (3) includes: dissolving the compound of formula (2) in a second solvent, and then adding TEMPO, sodium bicarbonate, tetrabutylammonium bromide, and NCS to cause an oxidation reaction, The compound of formula (3) is obtained.
- step (c) the Wittig reaction means that the compound of formula (3) and ethoxyformylmethylenetriphenylphosphine are dissolved in a third solvent to cause a Wittig reaction to obtain a compound of formula (6).
- the molar ratio of the compound of formula (3) to ethoxyformylmethylenetriphenylphosphine is 1:(1-5); preferably, it is 1:2.
- the third solvent is selected from one or more of benzene, toluene, ethyl acetate, tetrahydrofuran, hexane, etc.; preferably, toluene.
- the temperature of the Wittig reaction is 80-130°C; preferably, it is 110°C.
- the time of the Wittig reaction is 2-8h; preferably, it is 4h.
- the Wittig reaction means that the compound of formula (3), sodium hydride, and triethyl phosphonoacetate are dissolved in a third solvent to cause a Wittig reaction to obtain a compound of formula (6).
- the molar ratio of the compound of formula (3), sodium hydride, and triethyl phosphonoacetate is 1:(1-5):(1-5); preferably, it is 1:1.5:1.5.
- the third solvent is selected from one or more of benzene, toluene, ethyl acetate, tetrahydrofuran, hexane, etc.; preferably, it is tetrahydrofuran.
- the temperature of the Wittig reaction is 0-30°C; preferably, it is 0°C.
- the time of the Wittig reaction is 2-8h; preferably, it is 4h.
- the synthesis steps of the compound of formula (6) include: compound of formula (3), ethoxyformylmethylene triphenylphosphine or compound of formula (3), sodium hydride, triethyl phosphonoacetate Dissolved in the third solvent, Wittig reaction occurs to obtain the compound of formula (6).
- the oxidation reaction refers to: the compound of formula (6), oxidant, N-hydroxyphthalimide (NHPI), and acetic acid are dissolved in the fourth solvent to undergo oxidation reaction to obtain formula ( 7) Compound.
- the oxidant is selected from one or more of Na 2 Cr 2 O 7 , K 2 Cr 2 O 7 , PDC, BPO, etc.; preferably, it is PDC.
- step (d) the molar ratio of the compound of formula (6), oxidant, N-hydroxyphthalimide (NHPI), and acetic acid is 1: (1-5): (1-5): (0- 5); Preferably, it is 1:1.1:1.1:0.
- the fourth solvent is selected from toluene, acetone, acetonitrile, water, dichloromethane, N,N-dimethylformamide, ethyl acetate, tert-butanol, N-methylpyrrolidone, etc.
- step (d) the temperature of the oxidation reaction is 0-50°C; preferably, it is room temperature 25°C.
- step (d) the oxidation reaction time is 10 to 48 hours; preferably, it is 20 hours.
- the synthesis step of the compound of formula (7) includes: dissolving the compound of formula (6) in a fourth solvent, adding PDC and NHPI, and performing an oxidation reaction to obtain the compound of formula (7).
- step (e) the deglycol protection reaction means that the compound of formula (7) and the acid are dissolved in the fifth solvent, and the deglycol protection reaction occurs to obtain the compound of formula (8).
- step (e) the molar ratio of the compound of formula (7) to the acid is 1:(1-50); preferably, it is 1:5.
- the acid is selected from one or more of concentrated sulfuric acid, concentrated hydrochloric acid, p-toluenesulfonic acid, etc.; preferably, concentrated sulfuric acid.
- step (e) the temperature of the hydrolysis reaction is 0-50°C; preferably, it is room temperature 25°C.
- step (e) the hydrolysis reaction time is 1-10h; preferably, it is 4h.
- the synthesis step of the compound of formula (8) includes: dissolving the compound of formula (7) in a fifth solvent, adding concentrated sulfuric acid, and undergoing a hydrolysis reaction to obtain the compound of formula (8).
- step (f) the molar ratio of the compound of formula (8) to the base is 1:(1-5); preferably, it is 1:2.
- step (f) the mass ratio of the compound of formula (8) to Raney nickel is 1:(0.1-5); preferably, it is 1:1.
- the base is selected from one or more of sodium tert-butoxide, potassium tert-butoxide, sodium ethoxide, sodium methoxide, sodium hydroxide, potassium hydroxide, etc.; preferably, tert-butanol sodium.
- the catalyst is selected from one or more of Raney nickel and the like. Preferably, it is Raney nickel.
- step (f) the temperature of the hydrolysis and reduction reaction is 20-100°C; preferably, it is 90°C.
- step (f) the time for the hydrolysis and reduction reaction is 24 to 72 hours; preferably, it is 48 hours.
- step (f) the reaction is carried out under the condition of hydrogen pressurization, and the pressure range of the hydrogen is 0.1-10 MPa; preferably, it is 4.0 MPa.
- the synthesis step of the compound of formula (9) includes: dissolving the compound of formula (8) in a sixth solvent, adding Raney nickel and sodium tert-butoxide in sequence, and reacting to obtain the compound of formula (9) ursodeoxy cholic acid.
- step (g) the oxidation reaction means that BA, TEMPO, sodium bicarbonate, tetrabutylammonium bromide, and an oxidizing agent represented by formula (1) are dissolved in the seventh solvent to undergo oxidation reaction to obtain formula ( 4) Compound.
- the oxidant is selected from one of N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), 2-iodoyl benzoic acid (IBX), etc. or Multiple; preferably, N-chlorosuccinimide (NCS).
- step (g) the molar ratio of BA, TEMPO, sodium bicarbonate, tetrabutylammonium bromide, and oxidant represented by formula (1) is 1: (0-1): (0-20): (0- 1): (1-5); preferably, 1:0.01:1.35:0.1:1.15.
- the seventh solvent is selected from one or more of dichloromethane, tetrahydrofuran, toluene, dimethyl sulfoxide, water, etc.; preferably, it is a mixed solvent of dichloromethane and water.
- step (g) the temperature of the oxidation reaction is 0-30°C; preferably, it is 0°C.
- step (g) the oxidation reaction time is 2-8h; preferably, it is 5h.
- the synthesis step of the compound of formula (4) includes: dissolving BA represented by formula (1) in a seventh solvent, and then adding TEMPO, sodium bicarbonate, tetrabutylammonium bromide, and NCS to produce The oxidation reaction yields the compound of formula (4).
- the Wittig reaction refers to: a compound of formula (4), methoxyformylmethylenetriphenylphosphine or ethoxyformylmethylenetriphenylphosphine or propoxyformylmethylene Triphenylphosphine is dissolved in the eighth solvent, Wittig reaction occurs, and the compound of formula (5) is obtained.
- the molar ratio of the compound of formula (4), methoxyformylmethylenetriphenylphosphine or ethoxyformylmethylenetriphenylphosphine or propoxyformylmethylenetriphenylphosphine is 1:( 1 to 5); preferably, 1:2.
- the eighth solvent is selected from one or more of benzene, toluene, ethyl acetate, tetrahydrofuran, hexane, etc.; preferably, toluene.
- the temperature of the Wittig reaction is 80-130°C; preferably, it is 110°C.
- the time of the Wittig reaction is 2-8h; preferably, it is 4h.
- step (h) the Wittig reaction means that the compound of formula (4), sodium hydride, diethyl phosphonoacetate or triethyl phosphonoacetate or propyl diethyl phosphonoacetate are dissolved in In the eighth solvent, Wittig reaction occurs to obtain the compound of formula (5).
- the eighth solvent is selected from one or more of benzene, toluene, ethyl acetate, tetrahydrofuran, hexane, etc.; preferably, it is tetrahydrofuran.
- the molar ratio of the compound of formula (4), sodium hydride, methyl phosphonoacetate diethyl or triethyl phosphonoacetate or propyl diethyl phosphonoacetate is 1:(1 ⁇ 5):(1 ⁇ 5); Preferably, it is 1:1.5:1.5.
- the temperature of the Wittig reaction is 0-30°C; preferably, it is 0°C.
- the time of the Wittig reaction is 2-8h; preferably, it is 4h.
- the synthesis step of the compound of formula (5) includes: compound of formula (4), ethoxyformylmethylene triphenylphosphine or compound of formula (4), sodium hydride, methyl phosphonoacetate two Ethyl or triethyl phosphonoacetate or propyl diethyl phosphonoacetate is dissolved in the eighth solvent, and Wittig reaction occurs to obtain the compound of formula (5).
- the ethylene glycol or neopentyl glycol protection reaction refers to: the compound of formula (5), ethylene glycol or neopentyl glycol, and p-toluenesulfonic acid are dissolved in the ninth solvent to produce ethylene glycol Protection reaction of alcohol or neopentyl glycol to obtain compound of formula (6); or, compound of formula (5), ethylene glycol or neopentyl glycol, p-toluenesulfonic acid, and triethyl orthoformate are dissolved in the ninth solvent,
- the protection reaction of ethylene glycol or neopentyl glycol occurs to obtain the compound of formula (6); preferably, the compound of formula (5), ethylene glycol or neopentyl glycol, and p-toluenesulfonic acid are dissolved in the ninth solvent to produce Ethylene glycol or neopentyl glycol protection reaction to obtain the compound of formula (6);
- the ninth solvent is selected from one or more of benzene, toluene, ethyl acetate, tetrahydrofuran, hexane, etc.; preferably, toluene.
- the ethylene glycol or neopentyl glycol protection reaction in step (i) is: the compound of formula (5), ethylene glycol or neopentyl glycol, and p-toluenesulfonic acid are dissolved in the ninth solvent, ethylene glycol Or neopentyl glycol protection reaction to obtain a compound of formula (6), wherein the molar ratio of the compound of formula (5), ethylene glycol or neopentyl glycol, and p-toluenesulfonic acid is 1: (1-50): (0.01 -1), preferably 1:10:0.01; the temperature of the ethylene glycol or neopentyl glycol protection reaction is 80-130°C, preferably 110°C; the ethylene glycol or neopentyl glycol protection reaction temperature
- the time is 2 to 36 hours, preferably 24 hours.
- the compound of formula (5), ethylene glycol or neopentyl glycol, p-toluenesulfonic acid, and triethyl orthoformate are dissolved in the ninth solvent
- the compound of formula (6) is obtained, wherein the moles of the compound of formula (5), ethylene glycol or neopentyl glycol, p-toluenesulfonic acid, and triethyl orthoformate
- the ratio is 1: (1-50): (0.01-1): (1-20); preferably, 1:10:0.1:3;
- the protection reaction temperature of ethylene glycol or neopentyl glycol is 0 ⁇ 50°C, preferably room temperature 25°C;
- the time for the ethylene glycol or neopentyl glycol protection reaction is 2 to 36 hours, preferably 8 hours.
- the synthesis step of the compound of formula (6) includes: dissolving the compound of formula (5) in a ninth solvent, reacting with ethylene glycol, neopentyl glycol, and p-toluenesulfonic acid to protect formula (5)
- the 3-position carbonyl group of the compound yields the compound of formula (6).
- the present invention also provides compounds represented by formula (6'), formula (6"), formula (7'), formula (7") or formula (8)
- R is an alkyl group; preferably a C1-C20 alkyl group; more preferably, a C1, C2 alkyl group.
- the compound represented by the formula (6) of the present invention includes a compound of the formula (6′) and a compound of the formula (6"), wherein the compound of the formula (6′) includes a compound of the formula (6′-A) and a compound of the formula (6′-B) Compounds, compounds of formula (6'-C), etc.; compounds of formula (6") include compounds of formula (6"-A), compounds of formula (6"-B), compounds of formula (6"-C), and the like.
- the compound represented by the formula (7) of the present invention includes a compound of the formula (7′) and a compound of the formula (7"), wherein the compound of the formula (7′) includes a compound of the formula (7′-B), etc.; a compound of the formula (7") Including compounds of formula (7"-B) and the like.
- the beneficial effects of the present invention include that in the preparation method of ursodeoxycholic acid of the present invention, the raw material BA used is a plant-derived raw material, which avoids the problem of pathogenic bacteria and virus infection, and is cheap and easy to obtain; the operation of the ursodeoxycholic acid synthesis step Simple, high yield, environmentally friendly, mild reaction conditions, simple post-treatment, low cost, and convenient for industrial production.
- Figure 1 shows the TLC detection result of the compound of formula (10) oxidized by PDC in Comparative Example 1.
- Figure 2 shows the TLC detection result of the compound of formula (11) oxidized by PDC in Comparative Example 1.
- Figure 3 shows the TLC detection result of the compound of formula (8) reduced by Pd/CH 2 in Comparative Example 2.
- Figure 4 shows the TLC detection result of the compound of formula (8) reduced by NaBH 4 in Comparative Example 2.
- BA (10.0 g, 30.26 mmol), p-toluenesulfonic acid (57 mg, 0.30 mmol), ethylene glycol (16.8 mL, 302.60 mmol) and 300 mL of benzene were sequentially added into a 250 mL single-neck flask, and the reaction was carried out under reflux and water separation for 24 hours. After the reaction is cooled, add 20 mL of saturated sodium bicarbonate solution and stir for 10 min. After concentration under reduced pressure, add 100 mL of water, extract with ethyl acetate (60 mL ⁇ 3), wash with water (50 mL ⁇ 2), and wash with saturated sodium chloride solution (50 mL).
- BA 5.0 g, 15.13 mmol
- IBX 8.5 g, 30.26 mmol
- 50 mL THF 50 mL DMSO were sequentially added to a 250 mL single-neck flask, and reacted at room temperature for 5 hours.
- reaction solution was added with 30 mL saturated NaHCO 3 and stirred for 10 min, 100 mL of water was added, and extracted with ethyl acetate (50 mL*3). The organic phases were combined, washed with saturated brine (50 mL), and dried with anhydrous sodium sulfate. Concentrate under reduced pressure to obtain a pale yellow solid. The light yellow solid was added to 25 mL of ethanol, pulped at room temperature for 12 hours, and filtered with suction to obtain compound 6"-B (9g, white solid) with a molar yield of 74%.
- the present invention tested various oxidation reaction conditions (as shown in Table 1), and obtained the best oxidation reaction conditions (as shown in Table 1, Entry 23).
- the optimal reaction conditions are obtained by screening and optimizing the solvent, oxidant, and reaction temperature, that is, the optimal reaction solvent is acetone/water (9:1), the optimal oxidant is PDC, and the optimal reaction temperature is At 25°C, the reaction yield reached 85%.
- the present invention tested various reduction and hydrolysis reaction conditions (as shown in Table 2), and obtained the best reduction and hydrolysis reaction conditions (as shown in Table 2, Entry 12).
- the optimal reaction conditions are obtained by screening and optimizing the solvent, base and reaction temperature, that is, the optimal reaction solvent is 2-methyltetrahydrofuran/isopropanol (1:1, v/v).
- the preferred base is sodium tert-butoxide
- the optimal reaction temperature is 90°C
- the reaction yield reaches 87%.
- the compound of formula (8) (1.0g, 2.42mmol), 20mL of isopropanol, 1.0g of Raney Ni, H 2 (4.0MPa) were sequentially added to the autoclave, reacted at 90°C for 24 hours, and then potassium tert-butoxide ( 543mg, 4.84mmol), the reaction was continued at 90°C for 24 hours.
- the compound of formula (8) (1.0g, 2.42mmol), 20mL of isopropanol, 1.0g of Raney Ni, H 2 (4.0MPa) were added to the autoclave successively, reacted at 90°C for 24 hours, and then added sodium tert-butoxide ( 465mg, 4.84mmol), the reaction was continued at 90°C for 24 hours.
- the compound of formula (5-B) (1.0 g, 2.51 mmol), 10 mL of acetyl chloride and 10 mL of acetic anhydride were sequentially added to a 100 mL single-necked flask, and the reaction was refluxed for 4 hours. After the completion of the reaction, it was concentrated under reduced pressure to obtain the compound of formula (11) (1.1 g, white solid), which was directly used in the next step.
- the compound of formula (11) (1.1 g, 2.51 mmol), 18 mL of acetone, 2 mL of water, NHPI (444 mg, 2.76 mmol), PDC (1.0 g, 2.76 mmol) were sequentially added to a 100 mL single-necked flask, and the reaction was carried out at room temperature for 20 hours.
- reaction formula is as follows.
- the compound of formula (8) (1.0 g, 2.42 mmol), 20 mL of methanol, 0.1 g of 10% Pd/C, and H 2 (4.0 MPa) were sequentially added to the autoclave, and reacted at 60° C. for 24 hours.
- Pd/CH 2 is used to reduce the compound (8), the reaction result is complicated, and the compound of formula (14) is not isolated.
Abstract
Description
Claims (17)
- 一种以BA为原料合成熊去氧胆酸的方法,其特征在于,所述方法包括以下步骤:(a)在第一溶剂中,式(1)所示的BA经乙二醇保护,得到式(2)化合物;(b)在第二溶剂中,式(2)化合物经氧化反应,得到式(3)化合物;(c)在第三溶剂中,式(3)化合物经Wittig反应,得到式(6)化合物;(d)在第四溶剂中,式(6)化合物经氧化反应,得到式(7)化合物;(e)在第五溶剂中,式(7)化合物在酸作用下发生水解反应,脱乙二醇保护,得到式(8)化合物;(f)在第六溶剂中,在催化剂和氢气的作用下,在加压条件下,式(8)化合物与碱加热发生水解和还原反应,得到如式(9)所示的所述熊去氧胆酸;或,所述方法包括以下步骤:(g)在第七溶剂中,式(1)所示的BA经氧化反应,得到式(4)化合物;(h)在第八溶剂中,式(4)化合物经Wittig反应,得到式(5)化合物;(i)在第九溶剂中,式(5)化合物经乙二醇或新戊二醇保护,得到式(6)化合物;(d)在第四溶剂中,式(6)化合物经氧化反应,得到式(7)化合物;(e)在第五溶剂中,式(7)化合物在酸作用下发生水解反应,脱乙二醇或新戊二醇保护,得到式(8)化合物;(f)在第六溶剂中,在催化剂和氢气的作用下,在加压条件下,式(8)化合物与碱加热发生水解和还原反应,得到如式(9)所示的所述熊去氧胆酸;其中,所述方法的反应过程如路线(A)所示:
- 如权利要求1所述的方法,其特征在于,步骤(a)中,所述乙二醇保护反应是指:式(1)所示的BA、乙二醇、对甲苯磺酸溶解在第一溶剂中,发生乙二醇保护反应,得到式(2)化合物;其中,式(1)所示的BA、乙二醇、对甲苯磺酸的摩尔比为1:(1-50):(0.01-1);和/或,所述第一溶剂选自苯、甲苯、乙酸乙酯、四氢呋喃、己烷中的一种或多种;和/或,所述乙二醇保护反应的温度为80~130℃;和/或,所述乙二醇保护反应的时间为2~36h。
- 如权利要求1所述的方法,其特征在于,步骤(a)中,所述乙二醇保护反应是指:式(1)所示的BA、乙二醇、对甲苯磺酸、原甲酸三乙酯溶解在第一溶剂中,发生乙二醇保护反应,得到式(2)化合物;其中,式(1)所示的BA、乙二醇、对甲苯磺酸、原甲酸三乙酯的摩尔比为1:(1-50):(0.01-1):(1-20);和/或,所述第一溶剂选自苯、甲苯、乙酸乙酯、四氢呋喃、己烷中的一种或多种;和/或,所述乙二醇保护反应的温度为0~50℃;和/或,所述乙二醇保护反应的时间为2~36h。
- 如权利要求1所述的方法,其特征在于,步骤(b)中,所述氧化反应是指:式(2)化合物、TEMPO、碳酸氢钠、四丁基溴化铵、氧化剂溶解在第二溶剂中,发生氧化反应,得到式(3)化合物;其中,式(2)化合物、TEMPO、碳酸氢钠、四丁基溴化铵、氧化剂的摩尔比为1:(0-1):(0-20):(0-1):(1-5);和/或,所述氧化反应在氧化剂的作用下进行,其中,所述氧化剂选自N-氯代琥珀酰亚胺(NCS)、N-溴代琥珀酰亚胺(NBS)、2-碘酰基苯甲酸(IBX)中的一种或多种;和/或,所述第二溶剂选自二氯甲烷、四氢呋喃、甲苯、二甲基亚砜、水中的一种或多种;和/或,所述氧化反应的温度为0~30℃;和/或,所述氧化反应的时间为2~8h。
- 如权利要求1所述的方法,其特征在于,步骤(c)中,所述Wittig反应是指:式(3)化合物、乙氧甲酰基亚甲基三苯基膦溶解在第三溶剂中,发生Wittig反应,得到式(6)化合物;其中,式(3)化合物、乙氧甲酰基亚甲基三苯基膦的摩尔比为1:(1~5);和/或,所述第三溶剂选自苯、甲苯、乙酸乙酯、四氢呋喃、己烷中的一种或多种;和/或,所述Wittig反应的温度为80~130℃;和/或,所述Wittig反应的时间为2~8h。
- 如权利要求1所述的方法,其特征在于,步骤(c)中,所述Wittig反应是指:式(3)化合物、氢化钠、膦酰基乙酸三乙酯溶解在第三溶剂中,发生Wittig反应,得到式(6) 化合物;其中,式(3)化合物、氢化钠、膦酰基乙酸三乙酯的摩尔比为1:(1~5):(1~5);和/或,所述第三溶剂选自苯、甲苯、乙酸乙酯、四氢呋喃、己烷中的一种或多种;和/或,所述Wittig反应的温度为0~30℃;和/或,所述Wittig反应的时间为2~8h。
- 如权利要求1所述的方法,其特征在于,步骤(g)中,所述氧化反应是指:式(1)所示的BA、TEMPO、碳酸氢钠、四丁基溴化铵、氧化剂溶解在第七溶剂中,发生氧化反应,得到式(4)化合物;其中,式(1)化合物、TEMPO、碳酸氢钠、四丁基溴化铵、氧化剂的摩尔比为1:(0-1):(0-20):(0-1):(1-5);和/或,所述氧化反应在氧化剂的作用下进行,其中,所述氧化剂选自N-氯代琥珀酰亚胺(NCS)、N-溴代琥珀酰亚胺(NBS)、2-碘酰基苯甲酸(IBX)中的一种或多种;和/或,所述第七溶剂选自二氯甲烷、四氢呋喃、甲苯、二甲基亚砜、水中的一种或多种;和/或,所述氧化反应的温度为0~30℃;和/或,所述氧化反应的时间为2~8h。
- 如权利要求1所述的方法,其特征在于,步骤(h)中,所述Wittig反应是指:式(4)化合物、甲氧甲酰基亚甲基三苯基膦或乙氧甲酰基亚甲基三苯基膦或丙氧甲酰基亚甲基三苯基膦溶解在第八溶剂中,发生Wittig反应,得到式(5)化合物;其中,式(4)化合物、甲氧甲酰基亚甲基三苯基膦或乙氧甲酰基亚甲基三苯基膦或丙氧甲酰基亚甲基三苯基膦的摩尔比为1:(1~5);和/或,所述第八溶剂选自苯、甲苯、乙酸乙酯、四氢呋喃、己烷中的一种或多种;和/或,所述Wittig反应的温度为80~130℃;和/或,所述Wittig反应的时间为2~8h。
- 如权利要求1所述的方法,其特征在于,步骤(h)中,所述Wittig反应是指:式(4)化合物、氢化钠、膦酰基乙酸甲酯二乙酯或膦酰基乙酸三乙酯或膦酰基乙酸丙酯二乙酯溶解在第八溶剂中,发生Wittig反应,得到式(5)化合物;其中,所述第八溶剂选自苯、甲苯、乙酸乙酯、四氢呋喃、己烷中的一种或多种;和/或,式(4)化合物、氢化钠、膦酰基乙酸甲酯二乙酯或膦酰基乙酸三乙酯或膦酰基乙酸丙酯二乙酯的摩尔比为1:(1~5):(1~5);和/或,所述Wittig反应的温度为0~30℃;和/或,所述Wittig反应的时间为2~8h。
- 如权利要求1所述的方法,其特征在于,步骤(i)中,所述乙二醇或新戊二醇保护反应是指:式(5)化合物、乙二醇或新戊二醇、对甲苯磺酸溶解在第九溶剂中,发生乙二醇或新戊二醇保护反应,得到式(6)化合物;其中,式(5)化合物、乙二醇或新戊二醇、对甲苯磺酸的摩尔比为1:(1-50):(0.01-1);和/或,所述第九溶剂选自苯、甲苯、乙酸乙酯、四氢呋喃、己烷中的一种或多种;和/或,所述乙二醇或新戊二醇保护反应的温度为80~130℃;和/或,所述乙二醇或新戊二醇保护反应的时间为2~36h。
- 如权利要求1所述的方法,其特征在于,步骤(i)中,所述乙二醇或新戊二醇保护反应是指:式(5)化合物、乙二醇或新戊二醇、对甲苯磺酸、原甲酸三乙酯溶解在第九溶剂中,发生乙二醇保护反应,得到式(6)化合物;其中,式(5)化合物、乙二醇或新戊二醇、对甲苯磺酸、原甲酸三乙酯的摩尔比为1:(1-50):(0.01-1):(1-20);和/或,所述第九溶剂选自苯、甲苯、乙酸乙酯、四氢呋喃、己烷中的一种或多种;和/或,所述乙二醇或新戊二醇保护反应的温度为0~50℃;和/或,所述乙二醇或新戊二醇保护反应的时间为2~36h。
- 如权利要求1所述的方法,其特征在于,步骤(d)中,所述氧化反应是指:式(6)化合物、氧化剂、N-羟基邻苯二甲酰亚胺、乙酸溶解在第四溶剂中,发生氧化反应,得到式(7)化合物;其中,式(6)化合物、氧化剂、N-羟基邻苯二甲酰亚胺(NHPI)、乙酸的摩尔比为1:(1-5):(1~5):(0~5);和/或,其中,所述氧化剂选自Na 2Cr 2O 7、K 2Cr 2O 7、PDC、BPO中的一种或多种;和/或,所述第四溶剂选自甲苯、丙酮、乙腈、水、二氯甲烷、N,N-二甲基甲酰胺、乙酸乙酯、叔丁醇、N-甲基吡咯烷酮中的一种或多种;和/或,所述氧化反应的温度为0~50℃;和/或,所述氧化反应的时间为10~48h。
- 如权利要求1所述的方法,其特征在于,步骤(e)中,所述脱乙二醇或新戊二醇保护反应是指:式(7)化合物、酸溶解在第五溶剂中,发生脱乙二醇或新戊二醇保护反应,得到式(8)化合物;其中,式(7)化合物、酸的摩尔比为1:(1~50);和/或,所述第五溶剂选自四氢呋喃、乙酸乙酯、甲醇、二氯甲烷、乙醚、水、甲苯、丙酮中的一种或多种;和/或,所述酸选自浓硫酸、浓盐酸、对甲苯磺酸中的一种或多种;和/或,所述水解反应的温度为0~50℃;和/或,所述水解反应的时间为1~10h。
- 如权利要求1所述的方法,其特征在于,步骤(f)中,式(8)化合物、碱的摩尔比为1:(1~5);和/或,式(8)化合物、雷尼镍的质量比为1:(0.1~5);和/或,所述第六溶剂选自四氢呋喃、2-甲基四氢呋喃、异丙醇、叔丁醇、甲醇、乙醇中的一种或多种;和/或,所述碱选自叔丁醇钠、叔丁醇钾、乙醇钠、甲醇钠、氢氧化钠、氢氧化钾中的一种或多种;所述催化剂选自雷尼镍等中的一种或多种;和/或,所述水解和还原反应的温度为20~100℃;和/或,所述水解和还原反应的时间为24~72h;和/或,所述反应在氢气加压的条件下进行,所述氢气的压力范围为0.1~10MPa。
- 如权利要求16所述的化合物,其特征在于,R为C1~C20的烷基。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022552994A JP7365082B2 (ja) | 2019-12-03 | 2020-11-06 | Baを原料とするウルソデオキシコール酸の合成方法 |
US17/781,095 US20230039886A1 (en) | 2019-12-03 | 2020-11-06 | Method for synthesizing ursodeoxycholic acid using ba as raw material |
KR1020227017621A KR20220088765A (ko) | 2019-12-03 | 2020-11-06 | Ba를 원료로 하는 우르소데옥시콜산의 합성 방법 |
EP20897016.0A EP4071161A4 (en) | 2019-12-03 | 2020-11-06 | PROCESS FOR SYNTHESIS OF URSODEOXYCHOLIC ACID USING BA AS RAW MATERIAL |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911222943.8 | 2019-12-03 | ||
CN201911222943.8A CN111072744B (zh) | 2019-12-03 | 2019-12-03 | 一种以ba为原料合成熊去氧胆酸的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021109791A1 true WO2021109791A1 (zh) | 2021-06-10 |
Family
ID=70312828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/126922 WO2021109791A1 (zh) | 2019-12-03 | 2020-11-06 | 一种以ba为原料合成熊去氧胆酸的方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230039886A1 (zh) |
EP (1) | EP4071161A4 (zh) |
JP (1) | JP7365082B2 (zh) |
KR (1) | KR20220088765A (zh) |
CN (1) | CN111072744B (zh) |
WO (1) | WO2021109791A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11384116B2 (en) | 2020-08-21 | 2022-07-12 | Sandhill One, Llc | Methods of making cholic acid derivatives and starting materials therefor |
CN115286675A (zh) * | 2022-08-30 | 2022-11-04 | 湖北共同生物科技有限公司 | 一种黄体酮中间体的制备方法 |
WO2023081657A3 (en) * | 2021-11-02 | 2023-07-06 | Sandhill One, Llc | High purity non-animal derived udca |
WO2023081658A3 (en) * | 2021-11-02 | 2023-07-06 | Sandhill One, Llc | High purity non-animal derived tudca |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111072744B (zh) * | 2019-12-03 | 2021-09-14 | 江苏佳尔科药业集团股份有限公司 | 一种以ba为原料合成熊去氧胆酸的方法 |
CN113024624A (zh) * | 2019-12-25 | 2021-06-25 | 上海科胜药物研发有限公司 | 一种去氧胆酸的合成方法 |
CN111560045A (zh) * | 2020-06-23 | 2020-08-21 | 江苏佳尔科药业集团股份有限公司 | 一种以ba为原料合成石胆酸的方法 |
CN113248557A (zh) * | 2021-04-09 | 2021-08-13 | 华东师范大学 | 一种以ba为原料合成胆固醇的方法 |
CN115246867A (zh) * | 2021-04-27 | 2022-10-28 | 江苏佳尔科药业集团股份有限公司 | 一种以ba为原料合成7-酮基石胆酸的方法 |
CN113651866B (zh) * | 2021-08-02 | 2023-07-04 | 王涛 | 一种以21-羟基-20-甲基孕甾-4-烯-3-酮为原料合成胆固醇的新方法 |
CN113968890A (zh) * | 2021-11-15 | 2022-01-25 | 湖南科瑞生物制药股份有限公司 | 一种植物源7-酮基石胆酸异构体杂质的制备方法 |
CN116836214A (zh) * | 2022-03-25 | 2023-10-03 | 苏州恩泰新材料科技有限公司 | 一种7-酮石胆酸中间体的合成方法和应用 |
CN115536719B (zh) * | 2022-09-16 | 2024-02-09 | 江苏佳尔科药业集团股份有限公司 | 一种高纯度植物源7-酮基石胆酸的合成方法 |
CN115521964B (zh) * | 2022-09-19 | 2024-04-12 | 湖北共同生物科技有限公司 | 一种甾体激素药物中间体的制备方法 |
CN115594728B (zh) * | 2022-10-28 | 2024-01-26 | 湖南科瑞生物制药股份有限公司 | 一种3-酮-4,22-二烯石胆酸酯及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014020024A1 (en) | 2012-07-31 | 2014-02-06 | Erregierre S.P.A. | Process for preparing high purity ursodeoxycholic acid |
CN105503987A (zh) | 2015-12-28 | 2016-04-20 | 成都市新功生物科技有限公司 | 一种载铜活性炭催化氧化还原法用鹅去氧胆酸合成熊去氧胆酸的方法 |
CN111072744A (zh) * | 2019-12-03 | 2020-04-28 | 华东师范大学 | 一种以ba为原料合成熊去氧胆酸的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002300302B2 (en) * | 1996-12-06 | 2006-08-10 | Genaera Corporation | Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds |
JP4438308B2 (ja) * | 2003-04-07 | 2010-03-24 | 三菱化学株式会社 | ステロイド化合物の製造方法 |
EP1775304A4 (en) * | 2004-07-13 | 2010-04-28 | Mitsubishi Chem Corp | PROCESS FOR THE PRODUCTION OF STEROIDS |
CN103319560A (zh) * | 2013-01-04 | 2013-09-25 | 华东理工大学 | 一种熊去氧胆酸的制备方法 |
EP3328817A4 (en) * | 2015-07-30 | 2019-04-03 | Intercept Pharmaceuticals, Inc. | PROCESS FOR THE PRODUCTION OF GALLENIC ACIDS AND DERIVATIVES THEREOF |
GB201608779D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
GB201608777D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
CN106749469B (zh) | 2016-12-08 | 2019-08-02 | 青州市欣泰生物制品有限公司 | 一种熊去氧胆酸的制备方法 |
-
2019
- 2019-12-03 CN CN201911222943.8A patent/CN111072744B/zh active Active
-
2020
- 2020-11-06 EP EP20897016.0A patent/EP4071161A4/en active Pending
- 2020-11-06 JP JP2022552994A patent/JP7365082B2/ja active Active
- 2020-11-06 US US17/781,095 patent/US20230039886A1/en active Pending
- 2020-11-06 WO PCT/CN2020/126922 patent/WO2021109791A1/zh unknown
- 2020-11-06 KR KR1020227017621A patent/KR20220088765A/ko unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014020024A1 (en) | 2012-07-31 | 2014-02-06 | Erregierre S.P.A. | Process for preparing high purity ursodeoxycholic acid |
CN105503987A (zh) | 2015-12-28 | 2016-04-20 | 成都市新功生物科技有限公司 | 一种载铜活性炭催化氧化还原法用鹅去氧胆酸合成熊去氧胆酸的方法 |
CN111072744A (zh) * | 2019-12-03 | 2020-04-28 | 华东师范大学 | 一种以ba为原料合成熊去氧胆酸的方法 |
Non-Patent Citations (8)
Title |
---|
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 24, 2016, pages 3986 - 3993 |
CAS , no. 128-13-2 |
JOURNAL OF THE CHEMICAL SOCIETY PERKIN TRANSACTIONS, vol. 1, 1990, pages 1 - 3 |
SAMAJA GISELA A.; CASTRO OLGA; ALVAREZ LAUTARO D.; DANSEY MARIA V.; ESCUDERO DAIANA S.; VELEIRO ADRIANA S.; PECCI ADALI; BURTON GE: "27-Nor-Δ4-dafachronic acid is a synthetic ligand ofCaenorhabditis elegansDAF-12 rece", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 10, 28 March 2013 (2013-03-28), pages 2893 - 2896, XP028582269, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2013.03.071 * |
See also references of EP4071161A4 |
STEROIDS, vol. 76, 2011, pages 1397 - 1399 |
SYNTHESIS, vol. 48, 2016, pages 588 - 594 |
WANG JIE; GU XIANG-ZHONG; HE LI-MING; LI CHEN-CHEN; QIU WEN-WEI: "Synthesis of ursodeoxycholic acid from plant-source (20S)-21-hydroxy-20-methylpregn-4-en-3-one", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY., US, vol. 157, 14 February 2020 (2020-02-14), US, XP086083441, ISSN: 0039-128X, DOI: 10.1016/j.steroids.2020.108600 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11384116B2 (en) | 2020-08-21 | 2022-07-12 | Sandhill One, Llc | Methods of making cholic acid derivatives and starting materials therefor |
WO2023081657A3 (en) * | 2021-11-02 | 2023-07-06 | Sandhill One, Llc | High purity non-animal derived udca |
WO2023081658A3 (en) * | 2021-11-02 | 2023-07-06 | Sandhill One, Llc | High purity non-animal derived tudca |
CN115286675A (zh) * | 2022-08-30 | 2022-11-04 | 湖北共同生物科技有限公司 | 一种黄体酮中间体的制备方法 |
CN115286675B (zh) * | 2022-08-30 | 2024-02-27 | 湖北共同生物科技有限公司 | 一种黄体酮中间体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20230039886A1 (en) | 2023-02-09 |
JP2023500978A (ja) | 2023-01-11 |
EP4071161A4 (en) | 2024-04-10 |
KR20220088765A (ko) | 2022-06-28 |
CN111072744B (zh) | 2021-09-14 |
JP7365082B2 (ja) | 2023-10-19 |
EP4071161A1 (en) | 2022-10-12 |
CN111072744A (zh) | 2020-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021109791A1 (zh) | 一种以ba为原料合成熊去氧胆酸的方法 | |
WO2022228080A1 (zh) | 一种以ba为原料合成7-酮基石胆酸的方法 | |
WO2022213480A1 (zh) | 一种以ba为原料合成胆固醇的方法 | |
CN111560045A (zh) | 一种以ba为原料合成石胆酸的方法 | |
WO2013063859A1 (zh) | 醋酸乌利司他的制备方法及其中间体 | |
WO2023142888A1 (zh) | 一种高纯度植物源胆固醇的合成方法 | |
CN1257181C (zh) | 雄激素甾类化合物以及制备和使用它们的方法 | |
CN114874277B (zh) | 一种胆固醇的合成方法 | |
WO2023142890A1 (zh) | 一种高纯度胆固醇的合成方法 | |
He et al. | A facile synthesis of ursodeoxycholic acid and obeticholic acid from cholic acid | |
CN115536719B (zh) | 一种高纯度植物源7-酮基石胆酸的合成方法 | |
CN115884978A (zh) | 制备胆酸衍生物的方法及其原料 | |
CN115181150A (zh) | 一种由植物甾醇降解物合成熊去氧胆酸的方法 | |
WO2018010651A1 (zh) | 一种奥贝胆酸及其中间体的制备方法 | |
JP2004529160A (ja) | 胆汁酸の製造 | |
CN115466300A (zh) | 一种胆酸中间体a7及其合成方法 | |
JPH10507451A (ja) | 6−アザアンドロステノンの合成 | |
JPS5850240B2 (ja) | アンドロスタン系の新規なジエン誘導体の製造法 | |
EP0338065B1 (fr) | Derives de la 19-nor progesterone, leur preparation et leur utilisation | |
US4163744A (en) | Synthesis of steroids | |
WO2023179724A1 (zh) | 一种7-酮石胆酸中间体的合成方法和应用 | |
DK147684B (da) | Analogifremgangsmaade til fremstilling af 16alfa-ethyl-4,9,11-oestratrien-3-oner | |
WO2023179721A1 (zh) | 一种7-酮石胆酸中间体及其合成方法和应用 | |
CN117917425A (zh) | 一种植物源熊去氧胆酸的合成方法 | |
CA2037092C (en) | Bile acid unsaturated derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20897016 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022552994 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227017621 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020897016 Country of ref document: EP Effective date: 20220704 |